New Delhi: Prevest Denpro Limited (BSE Code: 543363), a leading homegrown manufacturer of dental materials, has announced its 9 months results for Fiscal Year 2022.
Jammu based Prevest DenPro was listed on BSE SME platform in September 2021. Established in 1999, the company has a successful track record of more than two decades in manufacturing over 100 dental products with export to more than 80 countries worldwide, which contributes 60% to the revenue.
Financial Highlights for the 9MFY2022:
* Total Revenue of Rs 29.54 crores
* EBITDA of Rs 12.91 crores
* Profit After Tax of Rs 9.11 crores
* EPS of Rs 7.59 per share
Financial Highlights for Q3FY2022:
* Total Revenue of Rs 11.79 crores
* EBITDA of Rs 5.26 crores
* Profit After Tax of Rs 3.75 crores
* EPS of Rs 3.13 per share
Commenting on the company’s financial performance, Mr Atul Modi, Chairman and Managing Director of Prevest DenPro said, “with our continuous efforts in the development of new products, aggressive marketing and brand promotion, our company continues to report strong financials with a healthy topline and bottom line.
The company has a strong network of more than 90 international dealers in more than 80 countries of Europe, South America, Middle East, Africa and Asia. We are making continuous efforts to spread our business in other countries.
The company also obtained USFDA approval for their dental cements products and expects to receive approval for few more products very soon. The company has also received MDSAP Certification and now it can export the products to Canada and Brazil. We expect to sell our products in USA, Canada and Brazil in the near future.
The company has obtained Saudi FDA approval and has already started export to Saudi Arabia where the products have been well accepted and we aim for a sizeable business coming from Saudi Arabia.
The company has undertaken expansion or modernization of existing factory, setting up a state-of-the-art research center, diversification into manufacture of oral hygiene, oral care products and biomaterials such as bone grafting materials and membranes which will immensely contribute to the revenue of the company and enhance its market position.”
